Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Protein Name: | OGT |
Gene Name: | OGT |
Protein Full Name: | UDP-N-acetylglucosamine--peptide N-acetylglucosami |
Alias: | EC 2.4.1.-; O-GlcNAc transferase p110; O-GlcNAc transferase subunit p110; OGT1; O-linked N-acetylglucosamine transferase 110 kDa subunit; UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa |
Mass (Da): | 116925 |
Number AA: | 1046 |
UniProt ID: | O15294 |
Locus ID: | 8473 |
COSMIC ID: | OGT |
Gene location on chromosome: | Xq13.1 |
Cancer protein type: | UNCLEAR |
Effect of cancer mutation on protein: | UNCLEAR |
Effect of active protein on cancer: | UNCLEAR |
Number of cancer specimens: | 19604 |
Percent of cancer specimens with mutations: | 0.83 |
General distribution of mutations: | Multi-site |
Location of most mutations: | Broad distribution of mutation sites with some point mutations , but no complex mutations, insertions or deletions. |
Normal role description: | OGT is a glycosyltransferase responsibe for catalyzing the addition of a single N-acetylglucosamine in O-glycosidic linkage to serine or threonine residues. This may take place at phosphorylation sites, and OGT may therefore be involved in controlling transcription and neurofilament assembly. Moreover, OGT can interact with a histone deacetylase complex by binding to co-repressor Sin3A, and repress transcription in parallel with histone deacetylation. Studies have shown that OGT can regulate tumour growth and invasion by altering glucose metabolism in breast cancer. Overexpression of the gene has also been implicated in diabetes and neurological diseases. |
Commentary on involvement of protein in cancer: | 1 pharyngeal sample was also mutated (mis-sense) |